Cutler Group LP Lipocine Inc. Transaction History

Cutler Group LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$0.73 - $1.34 $657 - $1,206	-900 Reduced 6.47%	13,000 $10,000
Q1 2022 Apr 14, 2022	BUY	$0.89 - $1.85 $801 - $1,665	900 Added 6.92%	13,900 $19,000
Q2 2018 Aug 10, 2018	SELL	$1.06 - $1.78 $624 - $1,048	-589 Reduced 4.33%	13,000 $16,000
Q1 2018 May 11, 2018	BUY	$1.18 - $3.46 $6,005 - $17,607	5,089 Added 59.87%	13,589 $20,000
Q4 2017 Jan 17, 2018	SELL	$3.36 - $4.35 $3,696 - $4,785	-1,100 Reduced 11.46%	8,500 $29,000
Q3 2017 Oct 17, 2017	BUY	$3.67 - $4.19 $35,232 - $40,224	9,600	9,600 $38,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $418M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.